| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Yellow Fever | 68 | 2024 | 76 | 8.870 |
Why?
|
| Yellow Fever Vaccine | 39 | 2024 | 42 | 7.810 |
Why?
|
| Yellow fever virus | 73 | 2024 | 77 | 7.580 |
Why?
|
| Viral Vaccines | 61 | 2025 | 345 | 7.140 |
Why?
|
| Ebola Vaccines | 12 | 2025 | 17 | 3.680 |
Why?
|
| Hemorrhagic Fever, Ebola | 13 | 2025 | 59 | 3.390 |
Why?
|
| Antibodies, Viral | 82 | 2025 | 1205 | 3.140 |
Why?
|
| Viral Envelope Proteins | 24 | 2025 | 155 | 3.130 |
Why?
|
| Encephalitis Virus, Japanese | 16 | 2023 | 22 | 2.630 |
Why?
|
| Ebolavirus | 11 | 2025 | 47 | 2.510 |
Why?
|
| Vaccines, Synthetic | 34 | 2025 | 322 | 2.370 |
Why?
|
| Encephalitis, Japanese | 15 | 2023 | 17 | 2.360 |
Why?
|
| Flavivirus | 20 | 2012 | 22 | 2.310 |
Why?
|
| Vaccines, Attenuated | 38 | 2022 | 176 | 2.220 |
Why?
|
| Vesicular Stomatitis | 6 | 2023 | 9 | 2.190 |
Why?
|
| Dengue | 24 | 2013 | 122 | 2.100 |
Why?
|
| Dengue Virus | 28 | 2016 | 134 | 2.070 |
Why?
|
| Disease Outbreaks | 38 | 2024 | 330 | 1.880 |
Why?
|
| Henipavirus Infections | 3 | 2025 | 6 | 1.860 |
Why?
|
| Vaccination | 30 | 2025 | 1019 | 1.800 |
Why?
|
| Bacterial Vaccines | 18 | 2005 | 103 | 1.790 |
Why?
|
| West Nile virus | 13 | 2013 | 117 | 1.740 |
Why?
|
| Smallpox Vaccine | 7 | 2008 | 38 | 1.590 |
Why?
|
| Urease | 19 | 2002 | 74 | 1.480 |
Why?
|
| Animals | 214 | 2025 | 36521 | 1.450 |
Why?
|
| Antibodies, Neutralizing | 17 | 2025 | 498 | 1.410 |
Why?
|
| Culicidae | 22 | 2023 | 75 | 1.360 |
Why?
|
| West Nile Virus Vaccines | 15 | 2013 | 19 | 1.340 |
Why?
|
| Drug Carriers | 7 | 2017 | 119 | 1.320 |
Why?
|
| Nipah Virus | 3 | 2025 | 6 | 1.280 |
Why?
|
| Japanese Encephalitis Vaccines | 11 | 2009 | 12 | 1.270 |
Why?
|
| Genetic Vectors | 11 | 2020 | 967 | 1.230 |
Why?
|
| Helicobacter Infections | 25 | 2004 | 1278 | 1.220 |
Why?
|
| Vaccines | 9 | 2023 | 380 | 1.220 |
Why?
|
| Helicobacter pylori | 26 | 2004 | 1335 | 1.190 |
Why?
|
| Neutralization Tests | 49 | 2024 | 238 | 1.180 |
Why?
|
| Aedes | 29 | 2018 | 109 | 1.120 |
Why?
|
| West Nile Fever | 9 | 2008 | 139 | 1.090 |
Why?
|
| Vaccinia virus | 7 | 2008 | 53 | 1.050 |
Why?
|
| Viremia | 25 | 2015 | 134 | 1.050 |
Why?
|
| Travel | 11 | 2014 | 125 | 1.040 |
Why?
|
| Chiroptera | 6 | 2023 | 17 | 0.980 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2025 | 114 | 0.970 |
Why?
|
| Flavivirus Infections | 5 | 2007 | 6 | 0.900 |
Why?
|
| Vero Cells | 20 | 2021 | 113 | 0.860 |
Why?
|
| Encephalitis, Viral | 1 | 2023 | 21 | 0.850 |
Why?
|
| Lassa virus | 15 | 2019 | 23 | 0.840 |
Why?
|
| Zoonoses | 7 | 2019 | 53 | 0.840 |
Why?
|
| Lassa Fever | 4 | 2019 | 12 | 0.810 |
Why?
|
| Antigens, Viral | 23 | 2017 | 440 | 0.800 |
Why?
|
| Humans | 212 | 2025 | 134196 | 0.800 |
Why?
|
| Macaca fascicularis | 13 | 2025 | 88 | 0.790 |
Why?
|
| Zika Virus | 2 | 2023 | 151 | 0.780 |
Why?
|
| Recombination, Genetic | 9 | 2016 | 453 | 0.770 |
Why?
|
| Epidemics | 3 | 2017 | 59 | 0.770 |
Why?
|
| Zika Virus Infection | 2 | 2023 | 175 | 0.760 |
Why?
|
| Africa | 15 | 2021 | 142 | 0.740 |
Why?
|
| Communicable Diseases | 4 | 2013 | 164 | 0.730 |
Why?
|
| Double-Blind Method | 20 | 2021 | 1664 | 0.700 |
Why?
|
| Macaca mulatta | 23 | 2022 | 513 | 0.700 |
Why?
|
| Immunization, Passive | 8 | 2022 | 129 | 0.690 |
Why?
|
| Virulence | 20 | 2019 | 279 | 0.660 |
Why?
|
| Vaccines, Inactivated | 7 | 2011 | 148 | 0.650 |
Why?
|
| Insect Vectors | 26 | 2013 | 114 | 0.640 |
Why?
|
| Escherichia coli Proteins | 8 | 2002 | 316 | 0.640 |
Why?
|
| Viral Nonstructural Proteins | 4 | 2013 | 193 | 0.640 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2019 | 67 | 0.630 |
Why?
|
| Vesiculovirus | 8 | 2021 | 16 | 0.630 |
Why?
|
| Immunoglobulins | 5 | 2013 | 171 | 0.590 |
Why?
|
| Antibodies, Bacterial | 16 | 2003 | 407 | 0.590 |
Why?
|
| Disease Models, Animal | 21 | 2025 | 4802 | 0.580 |
Why?
|
| Bacterial Toxins | 12 | 2005 | 177 | 0.580 |
Why?
|
| Membrane Glycoproteins | 5 | 2017 | 432 | 0.580 |
Why?
|
| Cricetinae | 18 | 2013 | 396 | 0.580 |
Why?
|
| Culex | 15 | 2018 | 34 | 0.570 |
Why?
|
| Encephalitis, St. Louis | 15 | 2004 | 20 | 0.570 |
Why?
|
| Mice | 68 | 2022 | 19045 | 0.570 |
Why?
|
| Enterotoxins | 12 | 2003 | 82 | 0.560 |
Why?
|
| Viral Plaque Assay | 14 | 2017 | 42 | 0.560 |
Why?
|
| Vaccinia | 3 | 2006 | 8 | 0.550 |
Why?
|
| Adjuvants, Immunologic | 13 | 2011 | 391 | 0.550 |
Why?
|
| Public Health | 6 | 2020 | 287 | 0.540 |
Why?
|
| Encephalitis Virus, St. Louis | 16 | 2004 | 18 | 0.540 |
Why?
|
| History, 20th Century | 9 | 2019 | 396 | 0.520 |
Why?
|
| Serial Passage | 3 | 2013 | 19 | 0.510 |
Why?
|
| History, 21st Century | 7 | 2019 | 277 | 0.510 |
Why?
|
| RNA, Viral | 16 | 2021 | 563 | 0.500 |
Why?
|
| Viral Proteins | 11 | 2009 | 360 | 0.500 |
Why?
|
| Virus Diseases | 16 | 2019 | 291 | 0.500 |
Why?
|
| Encephalomyelitis, Equine | 20 | 1993 | 24 | 0.500 |
Why?
|
| Genome, Viral | 6 | 2018 | 184 | 0.500 |
Why?
|
| Virus Replication | 22 | 2019 | 636 | 0.480 |
Why?
|
| Horse Diseases | 9 | 2008 | 37 | 0.480 |
Why?
|
| Antigens, Bacterial | 6 | 2001 | 320 | 0.460 |
Why?
|
| Gastritis | 5 | 2004 | 373 | 0.460 |
Why?
|
| Adult | 68 | 2025 | 31948 | 0.460 |
Why?
|
| Female | 107 | 2025 | 72037 | 0.460 |
Why?
|
| Cytomegalovirus Vaccines | 3 | 2022 | 6 | 0.450 |
Why?
|
| Genes, Viral | 10 | 2004 | 186 | 0.450 |
Why?
|
| Famous Persons | 1 | 2014 | 17 | 0.450 |
Why?
|
| Drug Evaluation, Preclinical | 6 | 2020 | 158 | 0.440 |
Why?
|
| Immunoglobulin A, Secretory | 5 | 2001 | 22 | 0.440 |
Why?
|
| Virology | 3 | 2014 | 36 | 0.440 |
Why?
|
| Endemic Diseases | 5 | 2014 | 59 | 0.430 |
Why?
|
| Vaccines, DNA | 4 | 2020 | 49 | 0.410 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2004 | 805 | 0.410 |
Why?
|
| Viral Structural Proteins | 1 | 2013 | 47 | 0.410 |
Why?
|
| Adaptation, Biological | 1 | 2013 | 36 | 0.410 |
Why?
|
| Horses | 15 | 2023 | 102 | 0.410 |
Why?
|
| Risk Assessment | 8 | 2020 | 3753 | 0.410 |
Why?
|
| South America | 11 | 2014 | 42 | 0.400 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 3978 | 0.400 |
Why?
|
| Hepatitis | 2 | 2023 | 57 | 0.400 |
Why?
|
| Disease Transmission, Infectious | 1 | 2013 | 87 | 0.390 |
Why?
|
| Bird Diseases | 5 | 2008 | 10 | 0.390 |
Why?
|
| Arbovirus Infections | 10 | 2016 | 31 | 0.380 |
Why?
|
| Adolescent | 41 | 2025 | 20646 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 12 | 1999 | 1066 | 0.370 |
Why?
|
| Dengue Vaccines | 2 | 2009 | 14 | 0.360 |
Why?
|
| Phylogeny | 7 | 2019 | 781 | 0.350 |
Why?
|
| Rodentia | 10 | 2019 | 48 | 0.350 |
Why?
|
| Chimera | 8 | 2006 | 88 | 0.350 |
Why?
|
| Male | 69 | 2025 | 66197 | 0.350 |
Why?
|
| T-Lymphocytes | 9 | 2022 | 1772 | 0.350 |
Why?
|
| Reassortant Viruses | 4 | 2004 | 34 | 0.340 |
Why?
|
| Immunoglobulin G | 17 | 2017 | 810 | 0.340 |
Why?
|
| Lymphocytic choriomeningitis virus | 4 | 2022 | 15 | 0.340 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 15 | 2017 | 855 | 0.330 |
Why?
|
| Nigeria | 19 | 2019 | 81 | 0.330 |
Why?
|
| Respiratory Tract Infections | 3 | 1999 | 295 | 0.320 |
Why?
|
| United States | 24 | 2023 | 11798 | 0.320 |
Why?
|
| Encephalitis Viruses, Japanese | 1 | 2009 | 1 | 0.320 |
Why?
|
| Viral Matrix Proteins | 3 | 2017 | 110 | 0.310 |
Why?
|
| RNA Viruses | 15 | 1992 | 36 | 0.310 |
Why?
|
| Mice, Inbred ICR | 8 | 2004 | 153 | 0.310 |
Why?
|
| Immunoglobulin A | 8 | 2004 | 217 | 0.310 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2008 | 15 | 0.300 |
Why?
|
| Multiple Organ Failure | 1 | 2010 | 144 | 0.300 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2010 | 198 | 0.300 |
Why?
|
| Vesicular stomatitis Indiana virus | 6 | 2021 | 9 | 0.290 |
Why?
|
| Bacterial Proteins | 3 | 2001 | 934 | 0.290 |
Why?
|
| Mutation, Missense | 1 | 2013 | 948 | 0.290 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 1161 | 0.290 |
Why?
|
| Mass Vaccination | 1 | 2008 | 14 | 0.290 |
Why?
|
| Cattle Diseases | 1 | 2008 | 22 | 0.290 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2011 | 130 | 0.290 |
Why?
|
| Monkeypox virus | 1 | 2007 | 5 | 0.280 |
Why?
|
| Amino Acid Substitution | 5 | 2013 | 417 | 0.280 |
Why?
|
| Birds | 17 | 2008 | 87 | 0.280 |
Why?
|
| Mosquito Vectors | 2 | 2018 | 37 | 0.280 |
Why?
|
| Swine | 7 | 2023 | 1213 | 0.280 |
Why?
|
| Immunization | 9 | 2002 | 315 | 0.280 |
Why?
|
| Autoimmunity | 1 | 2008 | 182 | 0.270 |
Why?
|
| Administration, Oral | 13 | 2002 | 725 | 0.270 |
Why?
|
| Cell Line | 15 | 2007 | 2863 | 0.270 |
Why?
|
| Bunyaviridae | 10 | 2018 | 10 | 0.270 |
Why?
|
| Disease Vectors | 7 | 2019 | 22 | 0.260 |
Why?
|
| Middle Aged | 38 | 2025 | 29414 | 0.260 |
Why?
|
| Dose-Response Relationship, Immunologic | 5 | 2016 | 108 | 0.260 |
Why?
|
| Young Adult | 10 | 2025 | 9961 | 0.260 |
Why?
|
| Survival Analysis | 6 | 2013 | 1595 | 0.260 |
Why?
|
| Mice, Inbred BALB C | 9 | 2022 | 1087 | 0.260 |
Why?
|
| Mesocricetus | 6 | 2011 | 74 | 0.260 |
Why?
|
| Health Policy | 1 | 2009 | 233 | 0.260 |
Why?
|
| Arboviruses | 16 | 1987 | 27 | 0.250 |
Why?
|
| Toxoids | 3 | 2005 | 7 | 0.250 |
Why?
|
| Severe Dengue | 3 | 2007 | 9 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1735 | 0.250 |
Why?
|
| Haplorhini | 16 | 2013 | 121 | 0.250 |
Why?
|
| Animal Use Alternatives | 1 | 2005 | 1 | 0.240 |
Why?
|
| Bioterrorism | 4 | 2007 | 11 | 0.240 |
Why?
|
| Antiviral Agents | 5 | 2007 | 824 | 0.240 |
Why?
|
| Immunocompetence | 1 | 2005 | 33 | 0.240 |
Why?
|
| Disease Reservoirs | 11 | 2003 | 37 | 0.240 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2004 | 7 | 0.230 |
Why?
|
| Smallpox | 1 | 2004 | 11 | 0.230 |
Why?
|
| Health Promotion | 1 | 2008 | 405 | 0.220 |
Why?
|
| Point Mutation | 2 | 2004 | 362 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 2 | 2017 | 227 | 0.220 |
Why?
|
| Hepatitis A | 2 | 2023 | 32 | 0.220 |
Why?
|
| Gastric Mucosa | 6 | 2003 | 493 | 0.220 |
Why?
|
| Glycoproteins | 3 | 2022 | 381 | 0.210 |
Why?
|
| Phosphoproteins | 2 | 2017 | 458 | 0.210 |
Why?
|
| Encephalomyelitis, Venezuelan Equine | 8 | 1992 | 16 | 0.210 |
Why?
|
| Agriculture | 1 | 2023 | 34 | 0.210 |
Why?
|
| Safety | 4 | 2008 | 217 | 0.210 |
Why?
|
| Helicobacter | 4 | 1997 | 18 | 0.210 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 12 | 1992 | 26 | 0.210 |
Why?
|
| World Health Organization | 4 | 2016 | 119 | 0.210 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2004 | 120 | 0.210 |
Why?
|
| Amino Acid Sequence | 9 | 2007 | 2793 | 0.210 |
Why?
|
| Immunity, Humoral | 1 | 2024 | 75 | 0.210 |
Why?
|
| Drug Industry | 2 | 2005 | 48 | 0.210 |
Why?
|
| Biotechnology | 2 | 2005 | 61 | 0.200 |
Why?
|
| Sierra Leone | 8 | 2019 | 31 | 0.200 |
Why?
|
| Rift Valley Fever | 2 | 2022 | 4 | 0.200 |
Why?
|
| Immunologic Memory | 5 | 2011 | 200 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 9 | 2016 | 1835 | 0.200 |
Why?
|
| Tropical Medicine | 3 | 2005 | 104 | 0.200 |
Why?
|
| Veterinary Medicine | 4 | 2008 | 8 | 0.200 |
Why?
|
| Rift Valley fever virus | 1 | 2022 | 5 | 0.200 |
Why?
|
| Base Sequence | 11 | 2007 | 3180 | 0.190 |
Why?
|
| Animals, Wild | 3 | 2013 | 29 | 0.190 |
Why?
|
| Lymphoid Tissue | 3 | 1998 | 49 | 0.190 |
Why?
|
| Bunyaviridae Infections | 5 | 2018 | 8 | 0.180 |
Why?
|
| Global Health | 4 | 2016 | 623 | 0.180 |
Why?
|
| Immunotherapy, Active | 1 | 2001 | 18 | 0.180 |
Why?
|
| Encephalitis Virus, Western Equine | 14 | 1993 | 14 | 0.180 |
Why?
|
| Respiratory Syncytial Viruses | 4 | 1999 | 153 | 0.180 |
Why?
|
| Escherichia coli | 6 | 2002 | 1032 | 0.180 |
Why?
|
| Genetic Variation | 6 | 2019 | 1630 | 0.180 |
Why?
|
| Administration, Intranasal | 6 | 1999 | 138 | 0.180 |
Why?
|
| Immunization, Secondary | 6 | 2022 | 113 | 0.180 |
Why?
|
| Off-Label Use | 1 | 2021 | 28 | 0.170 |
Why?
|
| Animals, Suckling | 5 | 2004 | 51 | 0.170 |
Why?
|
| Incidence | 7 | 2017 | 3424 | 0.170 |
Why?
|
| Cross Infection | 4 | 2019 | 344 | 0.170 |
Why?
|
| Europe | 2 | 2021 | 382 | 0.170 |
Why?
|
| History, 19th Century | 3 | 2010 | 120 | 0.170 |
Why?
|
| Nasal Mucosa | 2 | 1997 | 68 | 0.170 |
Why?
|
| Research | 3 | 2016 | 273 | 0.160 |
Why?
|
| HN Protein | 2 | 1996 | 18 | 0.160 |
Why?
|
| Arenavirus | 1 | 2019 | 3 | 0.160 |
Why?
|
| Kenya | 3 | 2021 | 63 | 0.160 |
Why?
|
| Immunization Schedule | 5 | 2003 | 107 | 0.160 |
Why?
|
| Arthropods | 2 | 2018 | 30 | 0.160 |
Why?
|
| Urban Health | 1 | 1999 | 79 | 0.150 |
Why?
|
| Marburgvirus | 1 | 1999 | 12 | 0.150 |
Why?
|
| Biological Warfare | 1 | 1998 | 3 | 0.150 |
Why?
|
| Injections, Intramuscular | 3 | 2017 | 198 | 0.150 |
Why?
|
| Encephalitis Virus, Eastern Equine | 5 | 1993 | 11 | 0.150 |
Why?
|
| Aged | 18 | 2024 | 21805 | 0.150 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1998 | 84 | 0.150 |
Why?
|
| Aging | 2 | 2005 | 1308 | 0.150 |
Why?
|
| DNA, Viral | 7 | 2005 | 500 | 0.150 |
Why?
|
| Cross Reactions | 7 | 2006 | 195 | 0.150 |
Why?
|
| Complement Fixation Tests | 16 | 1987 | 34 | 0.140 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 385 | 0.140 |
Why?
|
| Glycoconjugates | 1 | 1997 | 7 | 0.140 |
Why?
|
| Pestivirus | 1 | 2017 | 2 | 0.140 |
Why?
|
| Pestivirus Infections | 1 | 2017 | 2 | 0.140 |
Why?
|
| Violence | 1 | 1998 | 125 | 0.140 |
Why?
|
| Rats | 7 | 2022 | 3876 | 0.140 |
Why?
|
| Recombinant Proteins | 5 | 2015 | 1436 | 0.140 |
Why?
|
| Lectins | 1 | 1997 | 54 | 0.140 |
Why?
|
| Immunoglobulin M | 7 | 2002 | 219 | 0.140 |
Why?
|
| Antigens | 1 | 1997 | 153 | 0.140 |
Why?
|
| Ticks | 4 | 1992 | 33 | 0.140 |
Why?
|
| Disease Susceptibility | 2 | 2013 | 320 | 0.130 |
Why?
|
| Saliva | 4 | 1999 | 132 | 0.130 |
Why?
|
| SAIDS Vaccines | 1 | 2016 | 11 | 0.130 |
Why?
|
| Flaviviridae Infections | 1 | 2016 | 4 | 0.130 |
Why?
|
| Flaviviridae | 1 | 2016 | 5 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.130 |
Why?
|
| Drug Therapy, Combination | 4 | 2007 | 1183 | 0.130 |
Why?
|
| Brazil | 5 | 2024 | 138 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2013 | 1147 | 0.130 |
Why?
|
| Communicable Disease Control | 2 | 2016 | 142 | 0.130 |
Why?
|
| Guinea Pigs | 10 | 2017 | 171 | 0.130 |
Why?
|
| Ribavirin | 4 | 2007 | 89 | 0.130 |
Why?
|
| Biological Products | 1 | 1998 | 139 | 0.130 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 1999 | 377 | 0.130 |
Why?
|
| Developing Countries | 2 | 1999 | 289 | 0.130 |
Why?
|
| Antibody Specificity | 4 | 2007 | 203 | 0.130 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2016 | 100 | 0.130 |
Why?
|
| Hepatitis B | 2 | 2008 | 173 | 0.120 |
Why?
|
| Animals, Domestic | 3 | 2013 | 33 | 0.120 |
Why?
|
| Cattle | 7 | 2017 | 589 | 0.120 |
Why?
|
| Animals, Newborn | 4 | 2016 | 1041 | 0.120 |
Why?
|
| Chickens | 7 | 1993 | 640 | 0.120 |
Why?
|
| Arachnid Vectors | 2 | 1993 | 12 | 0.120 |
Why?
|
| Monkey Diseases | 5 | 2001 | 18 | 0.120 |
Why?
|
| Enterocolitis, Pseudomembranous | 3 | 2005 | 93 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2011 | 452 | 0.120 |
Why?
|
| Bluetongue virus | 1 | 1995 | 9 | 0.120 |
Why?
|
| Mucous Membrane | 2 | 1999 | 92 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 396 | 0.110 |
Why?
|
| Healthy Volunteers | 3 | 2022 | 153 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2016 | 273 | 0.110 |
Why?
|
| Virus Cultivation | 3 | 2004 | 77 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2018 | 343 | 0.110 |
Why?
|
| Argentina | 12 | 2004 | 54 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 1221 | 0.110 |
Why?
|
| Genetic Engineering | 2 | 2007 | 165 | 0.110 |
Why?
|
| Stomach | 6 | 1999 | 272 | 0.110 |
Why?
|
| Serologic Tests | 7 | 2008 | 130 | 0.110 |
Why?
|
| Injections, Subcutaneous | 2 | 2007 | 132 | 0.110 |
Why?
|
| Skin | 2 | 2008 | 545 | 0.110 |
Why?
|
| Conservation of Natural Resources | 1 | 2014 | 22 | 0.110 |
Why?
|
| Virion | 1 | 1995 | 151 | 0.110 |
Why?
|
| Antibody Formation | 7 | 2005 | 274 | 0.110 |
Why?
|
| Vibrio cholerae | 1 | 1994 | 29 | 0.110 |
Why?
|
| Serotyping | 7 | 2007 | 178 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 1984 | 258 | 0.110 |
Why?
|
| Species Specificity | 8 | 2018 | 570 | 0.110 |
Why?
|
| Fatal Outcome | 3 | 2010 | 378 | 0.110 |
Why?
|
| Diarrhea | 5 | 2005 | 343 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2022 | 1308 | 0.100 |
Why?
|
| Leukocyte Count | 4 | 2002 | 252 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 2170 | 0.100 |
Why?
|
| United Kingdom | 2 | 2005 | 242 | 0.100 |
Why?
|
| Peru | 4 | 2009 | 56 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2007 | 673 | 0.100 |
Why?
|
| Mites | 1 | 1993 | 4 | 0.100 |
Why?
|
| Child | 25 | 2017 | 25917 | 0.100 |
Why?
|
| Fever | 4 | 2017 | 312 | 0.100 |
Why?
|
| Rhabdoviridae | 2 | 1985 | 3 | 0.100 |
Why?
|
| Myocarditis | 2 | 2008 | 137 | 0.100 |
Why?
|
| Stomatitis | 3 | 1987 | 17 | 0.100 |
Why?
|
| Immunoglobulin Variable Region | 3 | 1999 | 52 | 0.100 |
Why?
|
| Oligoribonucleotides | 6 | 1986 | 9 | 0.100 |
Why?
|
| Climate | 5 | 2003 | 25 | 0.100 |
Why?
|
| Encephalitis | 3 | 2003 | 122 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 1998 | 658 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2017 | 13103 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2016 | 389 | 0.100 |
Why?
|
| Administration, Rectal | 3 | 2002 | 8 | 0.100 |
Why?
|
| Antigenic Variation | 2 | 2003 | 42 | 0.100 |
Why?
|
| Liver | 6 | 2003 | 1876 | 0.100 |
Why?
|
| Alanine Transaminase | 3 | 2002 | 162 | 0.100 |
Why?
|
| Hemagglutination Inhibition Tests | 13 | 1985 | 114 | 0.090 |
Why?
|
| Child, Preschool | 22 | 2005 | 14897 | 0.090 |
Why?
|
| Cations | 1 | 2011 | 39 | 0.090 |
Why?
|
| Viruses | 3 | 2016 | 128 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 6 | 1987 | 433 | 0.090 |
Why?
|
| Infant | 19 | 2005 | 13262 | 0.090 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 68 | 0.090 |
Why?
|
| Encephalitis, Tick-Borne | 2 | 2003 | 3 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 7239 | 0.090 |
Why?
|
| False Positive Reactions | 2 | 2008 | 146 | 0.090 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2011 | 62 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2013 | 874 | 0.090 |
Why?
|
| Epitopes | 6 | 1996 | 444 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 519 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2017 | 4882 | 0.090 |
Why?
|
| Liposomes | 1 | 2011 | 207 | 0.090 |
Why?
|
| Interferons | 2 | 2007 | 144 | 0.090 |
Why?
|
| Drug Approval | 2 | 2002 | 45 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2005 | 285 | 0.080 |
Why?
|
| Ecosystem | 2 | 2003 | 110 | 0.080 |
Why?
|
| Toxicity Tests | 1 | 2010 | 36 | 0.080 |
Why?
|
| Animal Diseases | 2 | 2008 | 7 | 0.080 |
Why?
|
| Bedbugs | 1 | 1989 | 9 | 0.080 |
Why?
|
| Cats | 2 | 2001 | 124 | 0.080 |
Why?
|
| Risk Factors | 8 | 2023 | 11189 | 0.080 |
Why?
|
| Cytokines | 2 | 2023 | 1397 | 0.080 |
Why?
|
| Sentinel Surveillance | 1 | 2009 | 24 | 0.080 |
Why?
|
| Age Factors | 8 | 2005 | 2997 | 0.080 |
Why?
|
| Headache | 3 | 2017 | 110 | 0.080 |
Why?
|
| Adaptation, Physiological | 2 | 2005 | 289 | 0.080 |
Why?
|
| Mosquito Control | 2 | 1988 | 36 | 0.070 |
Why?
|
| Seroconversion | 2 | 2021 | 15 | 0.070 |
Why?
|
| Brain | 7 | 1999 | 3226 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 5 | 2004 | 1626 | 0.070 |
Why?
|
| Vaccines, Subunit | 2 | 2022 | 70 | 0.070 |
Why?
|
| Syphilis | 1 | 2008 | 98 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2005 | 67 | 0.070 |
Why?
|
| Togaviridae Infections | 2 | 1984 | 3 | 0.070 |
Why?
|
| Alphavirus | 5 | 2006 | 18 | 0.070 |
Why?
|
| Acids | 1 | 2007 | 31 | 0.070 |
Why?
|
| HIV-1 | 2 | 1992 | 489 | 0.070 |
Why?
|
| Medicine | 1 | 2008 | 107 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 508 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 1332 | 0.070 |
Why?
|
| Microbial Viability | 1 | 2007 | 43 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 497 | 0.060 |
Why?
|
| Blood | 7 | 2019 | 108 | 0.060 |
Why?
|
| Malaria Vaccines | 1 | 2006 | 24 | 0.060 |
Why?
|
| Bedding and Linens | 1 | 2006 | 7 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 295 | 0.060 |
Why?
|
| DNA | 2 | 2011 | 1685 | 0.060 |
Why?
|
| Time Factors | 11 | 2004 | 6595 | 0.060 |
Why?
|
| Clothing | 1 | 2006 | 12 | 0.060 |
Why?
|
| Australia | 1 | 2006 | 186 | 0.060 |
Why?
|
| Ligands | 1 | 2007 | 573 | 0.060 |
Why?
|
| Sequence Alignment | 2 | 2004 | 633 | 0.060 |
Why?
|
| Encephalitis Viruses | 5 | 1981 | 5 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2005 | 32 | 0.060 |
Why?
|
| Hemorrhagic Fevers, Viral | 1 | 2005 | 2 | 0.060 |
Why?
|
| Rabbits | 4 | 2003 | 726 | 0.060 |
Why?
|
| Bangladesh | 1 | 2025 | 35 | 0.060 |
Why?
|
| RNA Virus Infections | 1 | 2005 | 7 | 0.060 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2004 | 182 | 0.060 |
Why?
|
| Pregnancy | 8 | 2019 | 7600 | 0.060 |
Why?
|
| Sindbis Virus | 1 | 1985 | 10 | 0.060 |
Why?
|
| Gambia | 6 | 2004 | 29 | 0.060 |
Why?
|
| Oligonucleotides | 3 | 1989 | 94 | 0.060 |
Why?
|
| Pericarditis | 1 | 2005 | 43 | 0.060 |
Why?
|
| Enzymes | 1 | 2005 | 50 | 0.060 |
Why?
|
| Gastric Acidity Determination | 1 | 2004 | 24 | 0.060 |
Why?
|
| Algorithms | 2 | 1999 | 1739 | 0.060 |
Why?
|
| Membrane Fusion | 1 | 2004 | 37 | 0.060 |
Why?
|
| Kinetics | 5 | 2007 | 1353 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2019 | 492 | 0.060 |
Why?
|
| History, 18th Century | 3 | 2008 | 70 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 100 | 0.050 |
Why?
|
| Bunyamwera virus | 3 | 1988 | 3 | 0.050 |
Why?
|
| Feces | 3 | 2001 | 789 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 1998 | 542 | 0.050 |
Why?
|
| Placebos | 2 | 2017 | 239 | 0.050 |
Why?
|
| Virus Assembly | 1 | 2004 | 47 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1193 | 0.050 |
Why?
|
| Consumer Product Safety | 2 | 2001 | 32 | 0.050 |
Why?
|
| North America | 3 | 2021 | 264 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 470 | 0.050 |
Why?
|
| Interleukins | 1 | 2004 | 130 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2005 | 3180 | 0.050 |
Why?
|
| Dyspepsia | 1 | 2004 | 108 | 0.050 |
Why?
|
| Alum Compounds | 2 | 2002 | 42 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2011 | 211 | 0.050 |
Why?
|
| Olfactory Mucosa | 1 | 1983 | 11 | 0.050 |
Why?
|
| Immunotherapy | 2 | 2001 | 750 | 0.050 |
Why?
|
| Encephalitis Viruses, Tick-Borne | 1 | 2003 | 2 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2005 | 245 | 0.050 |
Why?
|
| Models, Biological | 2 | 2002 | 1538 | 0.050 |
Why?
|
| Clone Cells | 1 | 2003 | 180 | 0.050 |
Why?
|
| Saimiri | 3 | 1998 | 11 | 0.050 |
Why?
|
| Omeprazole | 2 | 2003 | 102 | 0.050 |
Why?
|
| Escherichia coli Vaccines | 1 | 2002 | 11 | 0.050 |
Why?
|
| Influenza, Human | 2 | 2019 | 699 | 0.050 |
Why?
|
| Clarithromycin | 2 | 2003 | 127 | 0.050 |
Why?
|
| Contraindications | 1 | 2002 | 77 | 0.050 |
Why?
|
| Arthropod Vectors | 2 | 1999 | 18 | 0.050 |
Why?
|
| Infusions, Parenteral | 2 | 1999 | 100 | 0.050 |
Why?
|
| Liberia | 3 | 2017 | 8 | 0.050 |
Why?
|
| Uganda | 2 | 2021 | 89 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 3433 | 0.050 |
Why?
|
| Salmonella typhi | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunity, Mucosal | 2 | 2002 | 94 | 0.050 |
Why?
|
| Urbanization | 1 | 2002 | 7 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2003 | 162 | 0.050 |
Why?
|
| Reproduction | 1 | 1984 | 244 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2003 | 399 | 0.050 |
Why?
|
| Forecasting | 2 | 1996 | 377 | 0.050 |
Why?
|
| Sample Size | 1 | 2002 | 88 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2002 | 86 | 0.050 |
Why?
|
| Tropical Climate | 1 | 2002 | 51 | 0.050 |
Why?
|
| Platelet Count | 1 | 2002 | 144 | 0.050 |
Why?
|
| Animals, Outbred Strains | 1 | 2001 | 12 | 0.050 |
Why?
|
| Transcription, Genetic | 3 | 2004 | 1762 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2005 | 449 | 0.050 |
Why?
|
| 5' Untranslated Regions | 1 | 2002 | 61 | 0.050 |
Why?
|
| Cat Diseases | 1 | 2001 | 16 | 0.050 |
Why?
|
| Pyloric Antrum | 1 | 2001 | 63 | 0.050 |
Why?
|
| DNA Primers | 3 | 2002 | 672 | 0.050 |
Why?
|
| Pharyngitis | 1 | 2001 | 34 | 0.050 |
Why?
|
| Milk, Human | 1 | 2004 | 311 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2001 | 53 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2004 | 5465 | 0.040 |
Why?
|
| Jaundice | 1 | 2001 | 27 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2004 | 835 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2001 | 129 | 0.040 |
Why?
|
| Africa, Western | 4 | 1987 | 15 | 0.040 |
Why?
|
| Rodent Diseases | 3 | 1975 | 17 | 0.040 |
Why?
|
| Microscopy, Electron | 5 | 1996 | 367 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 204 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 269 | 0.040 |
Why?
|
| Immune Sera | 4 | 1985 | 94 | 0.040 |
Why?
|
| Vomiting | 1 | 2001 | 110 | 0.040 |
Why?
|
| Immunoglobulin Fragments | 2 | 1999 | 13 | 0.040 |
Why?
|
| Colorado | 5 | 1987 | 21 | 0.040 |
Why?
|
| Hemiptera | 1 | 1980 | 19 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 479 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2002 | 306 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 202 | 0.040 |
Why?
|
| Research Design | 2 | 2002 | 756 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2005 | 824 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2002 | 195 | 0.040 |
Why?
|
| Temperature | 4 | 1996 | 327 | 0.040 |
Why?
|
| Aluminum Hydroxide | 1 | 2000 | 39 | 0.040 |
Why?
|
| Adenoviridae | 2 | 2017 | 607 | 0.040 |
Why?
|
| Random Allocation | 2 | 1999 | 446 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2004 | 2588 | 0.040 |
Why?
|
| Animal Structures | 1 | 2019 | 14 | 0.040 |
Why?
|
| Genotype | 3 | 2004 | 2822 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 62 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 485 | 0.040 |
Why?
|
| Glycolipids | 1 | 1999 | 35 | 0.040 |
Why?
|
| Virus Shedding | 1 | 2019 | 82 | 0.040 |
Why?
|
| Respirovirus Infections | 1 | 1999 | 20 | 0.040 |
Why?
|
| Bolivia | 1 | 1999 | 15 | 0.040 |
Why?
|
| Serogroup | 1 | 2019 | 63 | 0.040 |
Why?
|
| Pharynx | 2 | 1996 | 69 | 0.040 |
Why?
|
| Antitoxins | 1 | 1999 | 7 | 0.040 |
Why?
|
| Salicylates | 1 | 1999 | 54 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1989 | 397 | 0.040 |
Why?
|
| Marburg Virus Disease | 1 | 1999 | 10 | 0.040 |
Why?
|
| Lizards | 1 | 1979 | 10 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1998 | 62 | 0.040 |
Why?
|
| Thailand | 3 | 2006 | 44 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 906 | 0.040 |
Why?
|
| Respiratory System | 1 | 1999 | 98 | 0.040 |
Why?
|
| Bismuth | 1 | 1999 | 83 | 0.040 |
Why?
|
| Capsid | 1 | 1999 | 147 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 1999 | 113 | 0.040 |
Why?
|
| Exercise | 1 | 2005 | 872 | 0.040 |
Why?
|
| Switzerland | 1 | 2018 | 15 | 0.040 |
Why?
|
| Drug Design | 1 | 1999 | 168 | 0.040 |
Why?
|
| Metronidazole | 1 | 1999 | 157 | 0.040 |
Why?
|
| Problem Solving | 1 | 1998 | 67 | 0.040 |
Why?
|
| International Agencies | 1 | 2018 | 31 | 0.040 |
Why?
|
| HIV Seropositivity | 2 | 2017 | 130 | 0.040 |
Why?
|
| Goats | 2 | 2017 | 60 | 0.040 |
Why?
|
| Primates | 1 | 1998 | 87 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1998 | 107 | 0.040 |
Why?
|
| Cholesterol | 1 | 2001 | 574 | 0.040 |
Why?
|
| Confidentiality | 1 | 1998 | 106 | 0.040 |
Why?
|
| Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate | 1 | 1997 | 3 | 0.040 |
Why?
|
| Galactosides | 1 | 1997 | 11 | 0.040 |
Why?
|
| Myalgia | 1 | 2017 | 10 | 0.040 |
Why?
|
| Risk | 2 | 1998 | 833 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 60 | 0.030 |
Why?
|
| Puerto Rico | 3 | 1989 | 52 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1997 | 98 | 0.030 |
Why?
|
| Sheep | 2 | 2017 | 233 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2001 | 519 | 0.030 |
Why?
|
| Internet | 1 | 2020 | 404 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 2017 | 75 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 1996 | 912 | 0.030 |
Why?
|
| Prognosis | 2 | 2023 | 5084 | 0.030 |
Why?
|
| HIV Infections | 1 | 1989 | 2073 | 0.030 |
Why?
|
| Integrins | 1 | 1997 | 103 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2011 | 536 | 0.030 |
Why?
|
| Vaccines, Combined | 1 | 2017 | 39 | 0.030 |
Why?
|
| Mexico | 3 | 2003 | 190 | 0.030 |
Why?
|
| Ecology | 3 | 1994 | 16 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2265 | 0.030 |
Why?
|
| Mammals | 2 | 2016 | 283 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 1997 | 1982 | 0.030 |
Why?
|
| Asia | 3 | 1986 | 127 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1997 | 344 | 0.030 |
Why?
|
| Metaplasia | 1 | 1997 | 219 | 0.030 |
Why?
|
| Cytotoxins | 1 | 1996 | 23 | 0.030 |
Why?
|
| Ferrets | 1 | 1996 | 14 | 0.030 |
Why?
|
| Roseolovirus | 1 | 2016 | 1 | 0.030 |
Why?
|
| Endoscopy | 1 | 1998 | 287 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2018 | 235 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 346 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2018 | 5219 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 157 | 0.030 |
Why?
|
| Freeze Drying | 1 | 1996 | 16 | 0.030 |
Why?
|
| Radioimmunoassay | 2 | 1986 | 111 | 0.030 |
Why?
|
| Drug Storage | 1 | 1996 | 18 | 0.030 |
Why?
|
| Drug Stability | 1 | 1996 | 62 | 0.030 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 1996 | 14 | 0.030 |
Why?
|
| Viral Fusion Proteins | 1 | 1996 | 76 | 0.030 |
Why?
|
| Recurrence | 3 | 2005 | 1470 | 0.030 |
Why?
|
| Clindamycin | 1 | 1995 | 42 | 0.030 |
Why?
|
| Formaldehyde | 1 | 1995 | 39 | 0.030 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 1995 | 9 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 192 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 827 | 0.030 |
Why?
|
| Jamaica | 2 | 1986 | 28 | 0.030 |
Why?
|
| Genes, Immunoglobulin | 1 | 1995 | 33 | 0.030 |
Why?
|
| Encephalitis, California | 2 | 1986 | 2 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 4008 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1135 | 0.030 |
Why?
|
| Plasmids | 3 | 2002 | 531 | 0.030 |
Why?
|
| Phenotype | 2 | 2001 | 4610 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 288 | 0.030 |
Why?
|
| Trypsin | 1 | 1994 | 94 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 411 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2001 | 704 | 0.030 |
Why?
|
| Colorado tick fever virus | 1 | 1993 | 2 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 825 | 0.030 |
Why?
|
| Antibody Affinity | 2 | 1999 | 41 | 0.030 |
Why?
|
| Mite Infestations | 1 | 1993 | 3 | 0.030 |
Why?
|
| Immunity, Active | 1 | 1973 | 6 | 0.030 |
Why?
|
| Protein Binding | 1 | 1997 | 1860 | 0.030 |
Why?
|
| Poultry Diseases | 1 | 1993 | 7 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 1995 | 331 | 0.030 |
Why?
|
| Antibodies, Heterophile | 1 | 1973 | 10 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1994 | 472 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 1992 | 24 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1992 | 41 | 0.020 |
Why?
|
| Mutagenesis | 2 | 2007 | 358 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1997 | 816 | 0.020 |
Why?
|
| Morbidity | 1 | 1993 | 256 | 0.020 |
Why?
|
| Utah | 1 | 1992 | 83 | 0.020 |
Why?
|
| Immunity | 1 | 1973 | 184 | 0.020 |
Why?
|
| DNA, Bacterial | 2 | 2003 | 498 | 0.020 |
Why?
|
| Thorium Dioxide | 1 | 1971 | 1 | 0.020 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2011 | 63 | 0.020 |
Why?
|
| Mononuclear Phagocyte System | 1 | 1971 | 9 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2011 | 14 | 0.020 |
Why?
|
| Latin America | 1 | 1991 | 99 | 0.020 |
Why?
|
| Autopsy | 2 | 2001 | 120 | 0.020 |
Why?
|
| Hemagglutination, Viral | 1 | 1970 | 10 | 0.020 |
Why?
|
| Factor V | 1 | 1971 | 17 | 0.020 |
Why?
|
| Myanmar | 2 | 1989 | 7 | 0.020 |
Why?
|
| Human Experimentation | 1 | 2011 | 36 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 265 | 0.020 |
Why?
|
| Necrosis | 3 | 1981 | 220 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 1998 | 4012 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2005 | 17579 | 0.020 |
Why?
|
| Agricultural Workers' Diseases | 2 | 1987 | 15 | 0.020 |
Why?
|
| Transformation, Genetic | 2 | 2002 | 36 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1993 | 563 | 0.020 |
Why?
|
| Urban Population | 3 | 2003 | 244 | 0.020 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1989 | 46 | 0.020 |
Why?
|
| Culture Techniques | 2 | 2005 | 81 | 0.020 |
Why?
|
| Hybridomas | 2 | 1995 | 41 | 0.020 |
Why?
|
| Encephalitis Virus, California | 2 | 1987 | 2 | 0.020 |
Why?
|
| Carrier State | 2 | 2004 | 78 | 0.020 |
Why?
|
| Antibodies | 4 | 1971 | 375 | 0.020 |
Why?
|
| Dogs | 2 | 1987 | 798 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1989 | 247 | 0.020 |
Why?
|
| Mutation | 1 | 2003 | 6350 | 0.020 |
Why?
|
| Organ Preservation | 1 | 1989 | 48 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1989 | 374 | 0.020 |
Why?
|
| Animal Welfare | 1 | 2008 | 3 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 2 | 1999 | 146 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1993 | 559 | 0.020 |
Why?
|
| Population Dynamics | 1 | 1988 | 34 | 0.020 |
Why?
|
| History of Medicine | 1 | 2008 | 5 | 0.020 |
Why?
|
| Geography | 5 | 1985 | 126 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2002 | 1764 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 701 | 0.020 |
Why?
|
| Seasons | 4 | 1988 | 334 | 0.020 |
Why?
|
| Sex Factors | 5 | 1988 | 1388 | 0.020 |
Why?
|
| Ruminants | 1 | 1987 | 2 | 0.020 |
Why?
|
| Carnivora | 1 | 1987 | 6 | 0.020 |
Why?
|
| Simuliidae | 1 | 1987 | 4 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2001 | 1138 | 0.020 |
Why?
|
| Virus Inactivation | 1 | 2007 | 9 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 1979 | 29 | 0.020 |
Why?
|
| Erythrocebus patas | 1 | 1987 | 4 | 0.020 |
Why?
|
| Cameroon | 1 | 1987 | 10 | 0.020 |
Why?
|
| Deer | 1 | 1987 | 15 | 0.020 |
Why?
|
| Environment | 1 | 2008 | 156 | 0.020 |
Why?
|
| Infant, Newborn | 7 | 2004 | 8639 | 0.020 |
Why?
|
| New Guinea | 1 | 1986 | 7 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 986 | 0.020 |
Why?
|
| Philippines | 1 | 1986 | 23 | 0.020 |
Why?
|
| Poxviridae | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cholera Toxin | 2 | 1997 | 52 | 0.020 |
Why?
|
| Complement Activation | 1 | 1986 | 53 | 0.020 |
Why?
|
| Biopsy | 2 | 2003 | 1303 | 0.020 |
Why?
|
| Measles virus | 1 | 2006 | 17 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 241 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1987 | 75 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1986 | 67 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1986 | 194 | 0.020 |
Why?
|
| Succinimides | 1 | 2005 | 7 | 0.020 |
Why?
|
| Immunoassay | 2 | 2001 | 138 | 0.020 |
Why?
|
| Spleen | 2 | 1981 | 289 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2005 | 36 | 0.020 |
Why?
|
| Gene Expression | 2 | 2003 | 1622 | 0.010 |
Why?
|
| Dermacentor | 1 | 1985 | 2 | 0.010 |
Why?
|
| Entomology | 1 | 1985 | 6 | 0.010 |
Why?
|
| Socioeconomic Factors | 2 | 1999 | 920 | 0.010 |
Why?
|
| Needles | 1 | 2005 | 52 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2005 | 57 | 0.010 |
Why?
|
| Saudi Arabia | 1 | 1985 | 56 | 0.010 |
Why?
|
| Togaviridae | 1 | 1984 | 1 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2005 | 106 | 0.010 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 1984 | 12 | 0.010 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2003 | 5 | 0.010 |
Why?
|
| Indian Ocean Islands | 1 | 1983 | 5 | 0.010 |
Why?
|
| Pacific Islands | 1 | 1983 | 5 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 2003 | 106 | 0.010 |
Why?
|
| Olfactory Nerve | 1 | 1983 | 2 | 0.010 |
Why?
|
| Exocrine Glands | 1 | 1983 | 8 | 0.010 |
Why?
|
| Avian Leukosis Virus | 1 | 1983 | 14 | 0.010 |
Why?
|
| Tennessee | 2 | 1985 | 34 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 151 | 0.010 |
Why?
|
| Breath Tests | 1 | 2003 | 186 | 0.010 |
Why?
|
| Encephalitis, Arbovirus | 1 | 1983 | 2 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 300 | 0.010 |
Why?
|
| Anti-Ulcer Agents | 1 | 2003 | 116 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1983 | 158 | 0.010 |
Why?
|
| Drug Contamination | 1 | 1983 | 38 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 334 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 237 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 1041 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 2 | 1973 | 67 | 0.010 |
Why?
|
| Avidin | 1 | 1982 | 19 | 0.010 |
Why?
|
| Amoxicillin | 1 | 2003 | 125 | 0.010 |
Why?
|
| Biotin | 1 | 1982 | 48 | 0.010 |
Why?
|
| Spinal Cord | 2 | 1981 | 275 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 124 | 0.010 |
Why?
|
| Prevalence | 2 | 2003 | 2684 | 0.010 |
Why?
|
| Methods | 2 | 1973 | 143 | 0.010 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 1981 | 22 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1981 | 51 | 0.010 |
Why?
|
| Anopheles | 3 | 1987 | 27 | 0.010 |
Why?
|
| Olfactory Bulb | 1 | 1983 | 103 | 0.010 |
Why?
|
| Laboratory Infection | 1 | 1981 | 1 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 454 | 0.010 |
Why?
|
| Illinois | 1 | 1981 | 16 | 0.010 |
Why?
|
| Endonucleases | 1 | 1981 | 59 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2002 | 206 | 0.010 |
Why?
|
| Dendrites | 1 | 1983 | 204 | 0.010 |
Why?
|
| Inclusion Bodies, Viral | 2 | 1978 | 11 | 0.010 |
Why?
|
| Colobus | 1 | 1980 | 1 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 277 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 1044 | 0.010 |
Why?
|
| Insecta | 1 | 1980 | 67 | 0.010 |
Why?
|
| Nervous System | 1 | 2001 | 131 | 0.010 |
Why?
|
| Poverty | 1 | 2003 | 438 | 0.010 |
Why?
|
| Axons | 1 | 1983 | 397 | 0.010 |
Why?
|
| Kidney | 2 | 1981 | 1404 | 0.010 |
Why?
|
| Missionaries | 1 | 1999 | 1 | 0.010 |
Why?
|
| Religious Missions | 1 | 1999 | 3 | 0.010 |
Why?
|
| Cecum | 1 | 1999 | 28 | 0.010 |
Why?
|
| Americas | 1 | 1979 | 52 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 1098 | 0.010 |
Why?
|
| Nucleotide Mapping | 2 | 1989 | 15 | 0.010 |
Why?
|
| Blood Glucose | 2 | 1980 | 1195 | 0.010 |
Why?
|
| Organelles | 1 | 1998 | 23 | 0.010 |
Why?
|
| Florida | 2 | 1988 | 79 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 1043 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1998 | 143 | 0.010 |
Why?
|
| Population Surveillance | 3 | 1985 | 419 | 0.010 |
Why?
|
| Ducks | 2 | 1987 | 5 | 0.010 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1995 | 11 | 0.010 |
Why?
|
| Neurons | 2 | 1983 | 2051 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1995 | 29 | 0.010 |
Why?
|
| Parasitic Diseases, Animal | 1 | 1975 | 1 | 0.010 |
Why?
|
| Patient Isolators | 1 | 1975 | 2 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1995 | 98 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1995 | 50 | 0.010 |
Why?
|
| Pseudogenes | 1 | 1995 | 53 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 3119 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1995 | 272 | 0.010 |
Why?
|
| Acute Disease | 1 | 1978 | 1190 | 0.010 |
Why?
|
| Prospective Studies | 3 | 1993 | 6612 | 0.010 |
Why?
|
| Urine | 1 | 1974 | 92 | 0.010 |
Why?
|
| Africa, Eastern | 1 | 1974 | 3 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1978 | 478 | 0.010 |
Why?
|
| Reptiles | 1 | 1974 | 2 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1979 | 897 | 0.010 |
Why?
|
| Hospital Units | 1 | 1973 | 19 | 0.010 |
Why?
|
| Transaminases | 1 | 1974 | 36 | 0.010 |
Why?
|
| Macaca | 1 | 1974 | 63 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1974 | 109 | 0.010 |
Why?
|
| Central Venous Pressure | 1 | 1973 | 26 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1974 | 49 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1998 | 937 | 0.010 |
Why?
|
| Heart | 1 | 1978 | 748 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1995 | 246 | 0.010 |
Why?
|
| Deafness | 1 | 1973 | 87 | 0.010 |
Why?
|
| Myocardium | 1 | 1978 | 1041 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1978 | 1006 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 1973 | 85 | 0.010 |
Why?
|
| Ethyl Ethers | 1 | 1972 | 1 | 0.010 |
Why?
|
| Floxuridine | 1 | 1972 | 9 | 0.010 |
Why?
|
| Deoxycholic Acid | 1 | 1972 | 14 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1972 | 66 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1972 | 59 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1992 | 318 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1972 | 199 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1973 | 296 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1993 | 273 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1971 | 43 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1971 | 66 | 0.010 |
Why?
|
| Dialysis | 1 | 1971 | 19 | 0.010 |
Why?
|
| Encephalomyelitis | 1 | 1971 | 5 | 0.010 |
Why?
|
| Immunoelectrophoresis | 1 | 1970 | 10 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1970 | 22 | 0.010 |
Why?
|
| Acetone | 1 | 1970 | 3 | 0.010 |
Why?
|
| Kaolin | 1 | 1970 | 2 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 610 | 0.010 |
Why?
|
| Absorption | 1 | 1970 | 53 | 0.010 |
Why?
|
| Calcium Chloride | 1 | 1970 | 23 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1970 | 52 | 0.010 |
Why?
|
| Sulfates | 1 | 1970 | 37 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1971 | 59 | 0.010 |
Why?
|
| Dextrans | 1 | 1970 | 47 | 0.010 |
Why?
|
| Larva | 1 | 1991 | 262 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1975 | 498 | 0.010 |
Why?
|
| Minnesota | 1 | 1970 | 181 | 0.010 |
Why?
|
| California | 1 | 1970 | 144 | 0.010 |
Why?
|
| Autoradiography | 1 | 1989 | 73 | 0.010 |
Why?
|
| Vietnam | 1 | 1989 | 65 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1989 | 231 | 0.000 |
Why?
|
| Ecuador | 2 | 1981 | 15 | 0.000 |
Why?
|
| HeLa Cells | 1 | 1990 | 838 | 0.000 |
Why?
|
| Health Surveys | 1 | 1989 | 262 | 0.000 |
Why?
|
| Epidemiologic Methods | 2 | 1981 | 111 | 0.000 |
Why?
|
| Codon | 1 | 1988 | 109 | 0.000 |
Why?
|
| Rural Health | 1 | 1988 | 52 | 0.000 |
Why?
|
| Biological Evolution | 1 | 1989 | 256 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 251 | 0.000 |
Why?
|
| Gene Frequency | 1 | 1989 | 780 | 0.000 |
Why?
|
| Feeding Behavior | 2 | 1987 | 731 | 0.000 |
Why?
|
| Geese | 1 | 1987 | 1 | 0.000 |
Why?
|
| Houseflies | 1 | 1987 | 3 | 0.000 |
Why?
|
| West Indies | 1 | 1986 | 6 | 0.000 |
Why?
|
| Inflammation | 1 | 1975 | 1595 | 0.000 |
Why?
|
| Exoribonucleases | 1 | 1986 | 24 | 0.000 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1986 | 140 | 0.000 |
Why?
|
| Michigan | 1 | 1985 | 52 | 0.000 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1986 | 295 | 0.000 |
Why?
|
| Demography | 1 | 1986 | 247 | 0.000 |
Why?
|
| Hospitalization | 1 | 1973 | 1913 | 0.000 |
Why?
|
| Equipment Design | 1 | 1985 | 609 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1982 | 311 | 0.000 |
Why?
|
| Senegal | 1 | 1981 | 1 | 0.000 |
Why?
|
| Chikungunya virus | 1 | 1981 | 28 | 0.000 |
Why?
|
| Panama | 1 | 1981 | 14 | 0.000 |
Why?
|
| Central America | 1 | 1980 | 20 | 0.000 |
Why?
|
| Military Medicine | 1 | 1981 | 51 | 0.000 |
Why?
|
| Glucagon | 1 | 1980 | 184 | 0.000 |
Why?
|
| Neoplasms | 1 | 1975 | 3035 | 0.000 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1979 | 7 | 0.000 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1979 | 22 | 0.000 |
Why?
|
| Ohio | 1 | 1979 | 87 | 0.000 |
Why?
|
| Leukocytosis | 1 | 1979 | 48 | 0.000 |
Why?
|
| Glucose Tolerance Test | 1 | 1980 | 227 | 0.000 |
Why?
|
| Cerebrospinal Fluid | 1 | 1979 | 99 | 0.000 |
Why?
|
| Galago | 1 | 1977 | 1 | 0.000 |
Why?
|
| Ovary | 1 | 1979 | 390 | 0.000 |
Why?
|
| Peptides | 1 | 1980 | 864 | 0.000 |
Why?
|
| Phagocytes | 1 | 1975 | 25 | 0.000 |
Why?
|
| Liver Glycogen | 1 | 1975 | 23 | 0.000 |
Why?
|
| Mitochondria, Liver | 1 | 1975 | 36 | 0.000 |
Why?
|
| Insulin | 1 | 1980 | 1260 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1975 | 230 | 0.000 |
Why?
|
| Semliki forest virus | 1 | 1974 | 5 | 0.000 |
Why?
|
| London | 1 | 1973 | 15 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1974 | 261 | 0.000 |
Why?
|
| Blood Cells | 1 | 1973 | 55 | 0.000 |
Why?
|
| Nausea | 1 | 1973 | 87 | 0.000 |
Why?
|
| Fever of Unknown Origin | 1 | 1973 | 45 | 0.000 |
Why?
|
| Lung | 1 | 1980 | 1578 | 0.000 |
Why?
|